EFPIA On Why More EU Drug Price Transparency Isn’t The Answer
Industry Body Also Addresses Public R&D Funding & Shortage Solutions
Executive Summary
As discussions continue over the European Commission’s plans to overhaul the EU pharmaceutical legislation, the R&D-based pharma industry body EFPIA says that any new pharma policy framework will need to be stable, fast, effective and globally competitive.